Cover Image
市場調查報告書

「超越藥品Beyond-the-Pill」服務&解決方案:是否將成為醫藥品公司的下一個境界?

Beyond-the-Pill Services and Solutions: Pharma's Next Frontier?

出版商 Datamonitor Healthcare 商品編碼 342054
出版日期 內容資訊 英文 46 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
「超越藥品Beyond-the-Pill」服務&解決方案:是否將成為醫藥品公司的下一個境界? Beyond-the-Pill Services and Solutions: Pharma's Next Frontier?
出版日期: 2015年02月16日 內容資訊: 英文 46 Pages
簡介

由於政府及醫療費支付者探索高用效率的治療法,各種數位健康科技擴大了患者可自行健康管理的機會,慢性疾病領域上競爭激烈化、價格壓力的擴大等要素,醫藥品業者不僅提供單純的藥劑,更需要可支援適當藥劑的利用之服務&解決方案。

本報告提供製藥企業針對不僅提供藥劑之「超越藥品Beyond-the-Pill」服務&解決方案所提供之服務相關調查,彙整這些服務&解決方案的促進要素,各種模式的實驗配合措施,各種方法和合作關係,主要的經營者案例研究,課題與市場機會等相關資訊。

圖表

摘要整理

  • 成果的重視和醫藥品公司環繞式服務的關注
  • 醫藥品公司:各種「超越藥品Beyond-the-Pill」解決方案的開拓
  • 從產品轉變到服務:需要策略性·文化性變化

醫藥品公司環繞式服務的輩受注目的理由

  • 醫藥品公司的「超越藥品Beyond-the-Pill」服務&解決方案的注目:各種推進因素
  • 各種「超越藥品Beyond-the-Pill」計劃:依然在實驗階段
  • 文獻

醫藥品公司的各種「超越藥品Beyond-the-Pill」模式的試用

  • 著重於慢性疾病 (合作夥伴和合作)
  • 「超越藥品Beyond-the-Pill」計劃的各種方法和合作關係
  • 文獻

「超越藥品Beyond-the-Pill」案例研究:課題與市場機會

  • AstraZeneca:Me&MyCOPD
  • Novartis:「Living Like You」&「SymTrac」線上MS地方機關
  • Novartis:NHS的合作「Mobile Eye Unit」
  • Novo Nordisk:「Cities Changing Diabetes」
  • Johnson & Johnson:NHS的合作「Care4Today」
  • Sanofi/Medtronic:托曳&設備組合式·各種服務
  • Merck & Co:子公司Vree Health
  • 文獻

服務的轉變:策略性·文化的變化是必須的

  • 醫藥品公司的「超越藥品Beyond-the-Pill」解決方案的利用:僅限於商業性回本的情況不明之下
  • 企業文化的變化
  • 超越了多專業性企業的合作
  • 文獻

附錄

圖表

目錄
Product Code: DMKC0135884

Payers and governments are striving toward cost-effective treatment outcomes and more efficient care, and waves of new digital health technologies are offering patients unprecedented opportunities to be more engaged in their own health management. Competition, both generic and innovator, is fierce in many chronic disease areas, and is intensified by continued pricing pressure. All of these forces are compelling pharmaceutical firms to not only deliver pills and injections, but to also consider offering services and solutions that support the appropriate use of such medicines.

These services go beyond the traditional adherence programs of the last couple of decades. They increasingly involve technologies and tools designed to influence lifestyle choices and gather physician-relevant data and real-world evidence that may direct future R&D. Many are built around partnerships with consumer-facing technology firms, governments, and payers to map out treatment gaps and improve patient access. Significantly, not all such tie-ups are directly linked to a particular brand or product.

This report addresses the following questions:

  • Which stakeholders is pharma targeting through beyond-the-pill services?
  • Which pharma's experiments with beyond-the-pill services have been successful and why?
  • When should pharma companies consider beyond-the-pill services?
  • What are the key challenges encountered when engaging in beyond-the-pill services?
  • What corporate and cultural obstacles need to be overcome to successfully design and deliver a beyond-the-pill service?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

  • 1. Outcomes focus drives pharma to look at wrap-around services
  • 2. Pharma companies are exploring a range of beyond-the-pill solutions
  • 3. Product-to-services transition demands strategic and cultural change

WHY PHARMA IS LOOKING AT WRAP-AROUND SERVICES

  • 1. A range of forces is compelling pharma to look at beyond-the-pill services and solutions.
  • 2. Beyond-the-pill programs remain experimental
  • 3. Bibliography

PHARMA IS TRIALING VARIOUS BEYOND-THE-PILL MODELS

  • 4. Focus is on chronic diseases, often with partners
  • 5. Selected beyond-the-pill programs illustrate the range of approaches and partnerships
  • 6. Bibliography

BEYOND-THE-PILL CASE STUDIES ILLUSTRATE CHALLENGES AND OPPORTUNITIES

  • 7. AstraZeneca - Me&MyCOPD
  • 8. Novartis - Living Like You & SymTrac online MS community
  • 9. Novartis - Mobile Eye Unit Partnership with NHS
  • 10. Novo Nordisk - Cities Changing Diabetes
  • 11. Johnson & Johnson - Care4Today NHS Partnership
  • 12. Sanofi/Medtronic - Drug-device combos and services
  • 13. Merck & Co - Vree Health subsidiary
  • 14. Bibliography

SHIFT TO SERVICES DEMANDS STRATEGIC AND CULTURAL CHANGES

  • 15. Pharma needs to use beyond-the-pill solutions only when necessary as commercial returns
  • remain uncertain
  • 16. Corporate culture must change
  • 17. Multidisciplinary and cross-company collaboration
  • 18. Bibliography

APPENDIX

  • 19. About the author
  • 20. Scope
  • 21. Methodology
Back to Top